Fig. 6: Pharmacological inhibition of IGF1R and ERK suppresses the growth of BRAFi-resistant cells following the loss of HAT1 expression. | Oncogenesis

Fig. 6: Pharmacological inhibition of IGF1R and ERK suppresses the growth of BRAFi-resistant cells following the loss of HAT1 expression.

From: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Fig. 6

a Immunoblotting for phospho- and total ERK in A375 cells expressing non-targeting NT or HAT1 sgRNAs. b Relative IGF1R mRNA levels in A375 cells expressing non-targeting NT or HAT1 sgRNAs was analyzed by qRT-PCR. Actin was used as internal control. c, e A375 or SKMEL-28 cells expressing a non-targeting (NT) sgRNA or HAT1 sgRNAs were treated with DMSO, BRAF inhibitor vemurafenib (3 μM), IGF1R inhibitor, BMS-754807 (1 μM) and ERK inhibitor, SCH772984 (1 μM) was analyzed by clonogenic assay. d, f Relative colony number for data presented in panels c and e. Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, calculated using Student’s t test.

Back to article page